Here’s Greenhaven Road Capital’s Views on Cellebrite (CLBT)

5 days ago 6

Soumya Eswaran

Mon, November 10, 2025 astatine 7:44 AM CST 3 min read

Greenhaven Road Capital, an concern absorption company, released its third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. In the 3rd quarter, the money returned astir -9%, bringing the YTD returns to astir -9%. The factors that affected the portfolio during the 4th included a deficiency of nonstop concern successful AI, nary overlap with the S&P 500 and Russell 2000, and insufficient ownership of small, precocious growth, yet unprofitable companies that person driven the caller rally and benefited from the existent AI landscape. In addition, you tin cheque the fund’s apical 5 holdings to find its champion picks for 2025.

In its third-quarter 2025 capitalist letter, Greenhaven Road Capital highlighted stocks specified arsenic Cellebrite DI Ltd. (NASDAQ:CLBT). Headquartered successful Petah Tikva, Israel, Cellebrite DI Ltd. (NASDAQ:CLBT) is simply a bundle institution that develops solutions for legally sanctioned investigations. The one-month instrumentality of Cellebrite DI Ltd. (NASDAQ:CLBT) was -21.27%, and its shares mislaid 16.17% of their worth implicit the past 52 weeks. On November 7, 2025, Cellebrite DI Ltd. (NASDAQ:CLBT) banal closed astatine $15.40 per share, with a marketplace capitalization of $3.765 billion.

Greenhaven Road Capital stated the pursuing regarding Cellebrite DI Ltd. (NASDAQ:CLBT) successful its 3rd 4th 2025 capitalist letter:

"Digital forensics endeavor bundle institution Cellebrite DI Ltd. (NASDAQ:CLBT) is different apical 5 holding that is down for the year. As the winners and losers of AI are being sorted out, bundle companies person been placed successful the loser bucket and bundle multiples person declined. Altimeter Capital’s information (link & link) indicates that the Enterprise Value to Next 12 Months Revenue for “medium growth” companies (those with maturation rates betwixt 15% and 25%), which astir intimately describes Cellebrite, declined from 10.6X astatine the commencement of the twelvemonth to 7.8X astatine the extremity of Q3. This implies a diminution of 26% connected this metric and a headwind for each mean maturation bundle companies.

Cellebrite DI Ltd. (NASDAQ:CLBT) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 38 hedge money portfolios held Cellebrite DI Ltd. (NASDAQ:CLBT) astatine the extremity of the 2nd quarter, up from 30 successful the erstwhile quarter. Cellebrite DI Ltd. (NASDAQ:CLBT) reported revenue of $113.3 cardinal successful Q2 2025, up 18% from Q2 2024, driven by subscription gross maturation of 21%. While we admit the imaginable of Cellebrite DI Ltd. (NASDAQ:CLBT) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.